Full-Time

Manufacturing Science and Technology Senior Scientist

Manufacturing Science and Technology

Nivagen Pharmaceuticals

Nivagen Pharmaceuticals

51-200 employees

Develops, acquires, and markets generic drugs

No salary listed

Sacramento, CA, USA

In Person

Sacramento metro area; relocation within ~40 miles may be required.

PhD

Category
Biology & Biotech (1)

Get referred to Nivagen Pharmaceuticals

See people who can refer or advise you

Requirements
  • Ph.D. or Postgraduate degree in Pharmacy, Pharmaceutical Sciences, Chemistry, or a related field.
  • 3+ years of hands-on experience in sterile/Injectable pharmaceutical formulation development.
  • Hands-on experience in lab and commercial scale development of complex injectable products.
  • Ability to work independently, prioritize tasks, and collaborate effectively with cross-functional teams.
  • Proven track record of successful formulation development and commercialization.
  • Must live in or be willing to move to the Sacramento Metropolitan Region (approximately 40 miles in radius).
  • In-depth understanding of regulatory requirements (FDA, EMA) and GMP
  • Demonstrated ability to conduct independent research and problem-solving.
  • Strong leadership, project management, and organizational skills.
Responsibilities
  • Lead process development and optimization efforts for new and existing products, ensuring that they meet both quality and regulatory standards.
  • Provide technical expertise in the scale-up of manufacturing processes, from laboratory to commercial production, ensuring process robustness and efficiency.
  • Represent product development or CMC development of complex sterile injectable products.
  • Collaborate with cross-functional teams including R&D, Quality, Operations, and Regulatory Affairs to resolve technical challenges and drive process improvements.
  • Develop and implement process monitoring and control strategies to ensure consistency, reproducibility, and efficiency in manufacturing processes.
  • Identify opportunities for process improvements, cost reductions, and risk mitigation in manufacturing operations
  • Apply scientific fundamentals and creative problem-solving skills to solve complex technical issues.
  • Prepare manufacturing batch records, technical reports, development reports, and CMC documents to support regulatory submissions (e.g., IND, NDA & ANDA’s).
  • Define scope, timeline, and resource needs of functional activities and keep team on schedule.
  • Identify and manage external vendors and partners when needed.
  • Provide mentorship and leadership to team members.
  • Stay up to date with the latest scientific advancements in formulation development and applying new technologies to improve product performance.
  • Ensure compliance with Good Manufacturing Practices (GMP), health and safety regulations, and other relevant industry standards.
  • Extended work hours may be occasionally required based on project needs.
  • Additional duties and assignments as needed.
Nivagen Pharmaceuticals

Nivagen Pharmaceuticals

View

Nivagen Pharmaceuticals develops, acquires, and sells generic prescription drugs and OTC products for the North American market. It leverages global partnerships with FDA-approved manufacturing facilities to deliver high-quality, affordable products and collaborates with the world’s best CROs and CRAMs to develop and manufacture niche generics. The company supports small FDA-qualified manufacturers entering the U.S. market and differentiates itself through its ability to launch new generic products and its strong sales and marketing team, rather than relying on a single manufacturing or development approach. Revenue comes from product development, co-development, acquisitions, in-licensing, and providing sales and marketing services. Nivagen aims to grow its portfolio by forging CRO/CRAM partnerships, acquiring existing products, and expanding its product lineup to capture a larger share of the evolving generic and OTC market in North America.

Company Size

51-200

Company Stage

Growth Equity (Venture Capital)

Total Funding

$26M

Headquarters

Sacramento, California

Founded

2009

Get referred to Nivagen Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PAI Pharma's January 6, 2026 acquisition brings Olympus-backed capital and distribution.
  • Owning the Sacramento site after February 2026 strengthens expansion and regulatory control.
  • Shortage-sensitive injectable demand supports faster commercialization for Nivagen's RTU pipeline.

What critics are saying

  • Nivagen's zinc oxide Class II recall, started October 31, 2025, remains ongoing.
  • California recalled atorvastatin tablets in September 2024 for a carbamazepine mix-up.
  • Repeated cGMP failures or sterile contamination would trigger FDA shutdowns and destroy hospital trust.

What makes Nivagen Pharmaceuticals unique

  • Sacramento's 100,000-square-foot sterile facility makes Nivagen unusually domestic for injectables.
  • Nivagen built over 20 ready-to-use sterile injectables before PAI Pharma's January 2026 acquisition.
  • Its 503B compounding and CDMO services target shortage-driven hospital demand directly.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

401 (k) savings plan

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-7%
PE Hub
Jan 6th, 2026
Olympus-backed PAI Pharma picks up Nivagen Pharmaceuticals

Olympus-backed PAI Pharma picks up Nivagen Pharmaceuticals. Headquartered in Greenville, South Carolina, PAI is a developer, manufacturer and marketer of oral liquid medicines. * Nivagen operates an aseptic manufacturing facility in Sacramento, California, designed to support the production of IV bags, vials, prefilled syringes, and cartridges * Nivagen was founded in 2009 PAI Pharma, which is backed by Olympus Partners, has acquired Nivagen Pharmaceuticals, Inc, a Sacramento, California-based pharmaceutical company. No financial terms were disclosed. Gain instant access to our expert editorial analysis and in-depth insight. Already have an account? Sign in.

Benzinga
Jan 6th, 2026
PAI Pharma acquires Nivagen to expand US sterile injectable manufacturing amid persistent drug shortages

PAI Pharma, a portfolio company of Olympus Partners, has acquired Nivagen Pharmaceuticals, a California-based pharmaceutical company specialising in ready-to-use sterile injectables. The deal expands PAI's domestic manufacturing capabilities and addresses persistent drug shortages in the US healthcare system. Nivagen operates a state-of-the-art aseptic manufacturing facility in Sacramento, producing IV bags, vials, prefilled syringes and cartridges. The company brings over 20 injectable products to complement PAI's existing sterile portfolio of approximately 10 products in development and four on the market. The acquisition aligns with growing efforts to reshore pharmaceutical production and reduce reliance on foreign supply chains. PAI Pharma was advised by Bourne Partners, Kirkland & Ellis and KPMG, whilst Olympus Partners provided backing for the transaction.

Private Equity Info
Aug 22nd, 2022
Corbel Capital Partners invests into Nivagen Pharmaceuticals, Inc.

Corbel Capital Partners invested in Nivagen Pharmaceuticals (Sacramento, CA, US), a specialty pharmaceuticals business that develops and sells generic and branded prescription drugs.